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Abstract We assessed clinical, molecular and muscle
histopathological features in five unrelated Italian DM1
patients carrying novel variant pathological expansions
containing CCG interruptions within the 30-end of the CTG
array at the DMPK locus, detected by bidirectional triplet
primed PCR (TP-PCR) and sequencing. Three patients had
a negative DM1 testing by routine long-range PCR; the
other two patients were identified among 100 unrelated
DM1 cases and re-evaluated to estimate the prevalence of
variant expansions. The overall prevalence was 4.8 % in
our study cohort. There were no major clinical differences
between variant and non-variant DM1 patients, except for
cognitive involvement. Muscle RNA-FISH, immunofluo-
rescence for MBNL1 and RT-PCR analysis documented
the presence of ribonuclear inclusions, their co-localization
with MBNL1, and an aberrant splicing pattern involved
in DM1 pathogenesis, without any obvious differences
between variant and non-variant DM1 patients. There-
fore, this study shows that the CCG interruptions at the
30-end of expanded DMPK alleles do not produce quali-
tative effects on the RNA-mediated toxic gain-of-func-
tion in DM1 muscle tissues. Finally, our results support
the conclusion that different patterns of CCG interrup-
tions within the CTG array could modulate the DM1
clinical phenotype, variably affecting the mutational
dynamics of the variant repeat.
Keywords Steinert’s disease  Myotonic dystrophy
type 1  Variant expansions
Introduction
Myotonic dystrophy type 1 (DM1, dystrophia myotonica,
Steinert’s disease; OMIM 160900) is a multisystem dis-
order affecting skeletal muscle and several other tissues,
including the heart, brain, smooth muscle, eye and the
endocrine system [1, 2].
The molecular defect underlying DM1 consists of an
abnormal expansion of a polymorphic CTG-repeat tract in
the 30 untranslated region (UTR) of the DMPK gene,
located on chromosome 19q13.2-q13.3 [3–5]. Normal
alleles at the DM1 locus contain 5 to 35 CTG repeats,
whereas pathogenic alleles range from 50 to more than
1,000 repeats [3, 5, 6].
While the wild-type CTG tract is relatively stable upon
transmission, both intermediate premutated alleles (range
35–49 CTG repeats, mostly identified in unaffected DM1
parents) and full-range expanded alleles (transmitted from
affected individuals) are biased toward expansion [7–9].
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Similar to other triplet repeats expansion diseases
(TREDs), the occurrence of a slipped-strand mispairing
within the repetitive sequences during a broad range of
DNA metabolic processes represents the most likely
mechanism underlying the mutational dynamics of DM1
expanded repeats [10]. DM1 is characterized by genetic
‘‘anticipation’’ through subsequent affected generations, a
phenomenon associated with an increase in the number of
repeats during intergenerational transmission [1, 2].
Moreover, the expanded CTG tract in DM1 shows somatic
instability leading to somatic mosaicism, which can par-
tially explain both the phenotypic variability among DM1
patients and the lack of clear-cut correlations between the
number of CTG repeats in leukocytes and the severity of
some clinical manifestations [2].
Recently, pathological ‘‘variant’’ expansions containing
sequence interruptions (CCG, CTC, and GGC repeats)
interspersed within the 30-end of the CTG array have been
reported in DM1 patients by two distinct studies, with an
estimated prevalence of 3–5 % of cases [11, 12].
As for other TREDs [13, 14], these studies documented
that the presence of interruptions within the CTG array at
the DM1 locus would stabilize the variant expanded alleles
during intergenerational transmission [11, 12]. They also
highlighted the recurrence of atypical symptoms in affected
individuals of some DM1 families carrying ‘‘variant’’
expansions [11]. This suggests that interruptions in the
regular primary structure of the CTG expansion could
modulate the clinical phenotype, either by increasing DNA
strand stability during cell divisions, or by producing
conformational changes of the variant RNA species with
effects on their toxic gain-of-function [11, 12].
In order to clarify these issues, we performed a detailed
clinical and muscle characterization in five unrelated Ital-
ian DM1 patients carrying novel ‘‘variant’’ expansions,
diagnosed in our study cohort including 103 DM1 families.
Analysis for variant CTG expansions performed on
DNA extracted from leukocytes included bidirectional TP-
PCR followed by sequencing studies [12, 15, 16].
The prevalence of variant expansions estimated in our
DM1 population was compared to literature data. Detailed
clinical features were assessed in the five variant DM1
patients.
Finally, in three patients we performed morphological
and molecular studies on muscle biopsies, including RNA
fluorescence in situ hybridization (RNA-FISH) combined
with immunofluorescence (IF) for MBNL1and RT-PCR
studies for INSR, TNNT2, RYR1, and CLCN1 RNAs, to
evaluate if the interruptions within the CTG array would
produce any effect on the RNA-mediated pathogenesis at
the muscle tissue level in DM1.
Materials and methods
The study design fulfilled the guidelines of the Ethical
Board of our Institution.
Patients
The clinical-diagnostic assessment included:
1. Neurological evaluation and scoring of the severity of
skeletal muscle involvement by means of the Muscular
Impairment Rating Scale (MIRS) [17].
2. Assessment of glucose metabolism, electrolytes, liver
and kidney function, serum electrophoresis, thyroid
and sexual hormones determination.
3. Standard EMG and nerve conduction studies with
bilateral examination of sural and tibial nerves with
F-waves studies.
4. Neuropsychological examination, as previously
reported [18]. Performances were considered either
pathological or normal according to cut-off scores
obtained by standardization studies, which also pro-
vided age and educational level–adjusted scores.
5. Pelvic and lower limb muscles MRI, performed by a
1.5-T system (Siemens Vision, Siemens, Erlangen,
Germany) equipped with a phase-array multicoil. The
studies included T1-weighted spin-echo (SE) T2-
weighted SE and fat-suppressed T2-weighted SE
sequences in both axial and coronal sections.
6. Standard cardiologic evaluation including basal ECG
recording, 24-h-Holter monitoring and echocardiogra-
phy. Recommendations for cardiac electrophysiologi-
cal studies (SEF) were given to patients in accordance
to the inclusion criteria of the RAMYD study [19].
7. Lung function parameters, including forced vital and
total lung capacities assessed by spirometric evalua-
tion. A chest X-ray and a nocturnal pulse-oximetry
were also performed in all patients.
8. An ophthalmologic evaluation including dilated fun-
dus and slit-lamp examinations, and tone audiometry
for hearing function assessment.
Clinical and diagnostic findings of patients 1–5 are
summarized in Table 1. Patients’ clinical data are reported
in the supplementary file, and neuropsychological tests
scores in the Table S1.
Patients 1–3 had previously tested negative for DM1.
We repeated DM1 testing by routine long-range (LR) PCR/
Southern blotting and the results were negative, with all
patients apparently being homozygotic for a wild-type
allele (Fig. 1) [20]. DM2 testing was negative too (data not
shown).
J Neurol
123
T
a
b
le
1
S
u
m
m
ar
y
o
f
th
e
cl
in
ic
al
fe
at
u
re
s
o
f
th
e
p
at
ie
n
ts
P
at
ie
n
t
(P
t)
A
g
e
A
g
e
at
o
n
se
t
(y
ea
rs
)
O
n
se
t
sy
m
p
to
m
s
F
am
il
y
h
is
to
ry
C
at
ar
ac
t
D
ia
b
et
es
T
h
y
ro
id
d
is
ea
se
P
u
lm
o
n
ar
y
fu
n
ct
io
n
te
st
s
C
ar
d
ia
c
sy
m
p
to
m
s
C
ar
d
ia
c
ev
al
u
at
io
n
N
eu
ro
p
sy
ch
o
lo
g
ic
al
ev
al
u
at
io
n
(N
P
E
)
E
M
G
an
d
N
C
S
M
IR
S
P
t
1
5
5
0
–
7
0
0
re
p
ea
ts
6
3
4
7
H
an
d
g
ri
p
m
y
o
to
n
ia
P
ro
g
re
ss
iv
e
d
is
ta
l
m
u
sc
le
w
ea
k
n
es
s
(l
o
w
er
li
m
b
s)
? (F
at
h
er
p
ro
b
ab
ly
af
fe
ct
ed
)
Y
es
N
o
F
o
ll
ic
u
la
r
ad
en
o
m
a
N
o
rm
al
N
o
n
e
T
ra
n
si
en
t
E
C
G
si
g
n
s
o
f
is
ch
ae
m
ia
b
y
n
eg
at
iv
e
m
y
o
ca
rd
ia
l
sc
in
ti
g
ra
p
h
y
S
in
u
s
b
ra
d
y
ca
rd
ia
,
R
B
B
B
,
o
cc
as
io
n
al
E
P
C
s
N
o
rm
al
M
y
o
to
n
ia
,
m
y
o
p
at
h
ic
re
cr
u
it
m
en
t,
n
o
n
eu
ro
p
at
h
y
4
P
t
2
6
0
0
–
8
3
0
re
p
ea
ts
5
2
4
7
H
an
d
g
ri
p
m
y
o
to
n
ia
P
ro
x
im
al
m
u
sc
le
w
ea
k
n
es
s
F
at
h
er
af
fe
ct
ed
Y
es
N
o
H
y
p
o
th
y
r.
N
o
rm
al
F
re
q
u
en
t
p
al
p
it
at
io
n
s
L
o
n
g
H
V
in
te
rv
al
([
7
0
m
s)
an
d
P
M
im
p
la
n
t.
L
at
er
IC
D
u
p
g
ra
d
e
b
ec
au
se
o
f
d
o
cu
m
en
te
d
n
o
n
-s
u
st
ai
n
ed
V
T
N
o
rm
al
M
y
o
to
n
ia
,
m
y
o
p
at
h
ic
re
cr
u
it
m
en
t,
n
o
n
eu
ro
p
at
h
y
3
P
t
3
6
5 r
ep
ea
ts
7
0
3
0
H
an
d
m
u
sc
le
w
ea
k
n
es
s
B
il
at
er
al
p
to
si
s
In
g
ra
v
es
ce
n
t
p
ro
x
im
al
m
u
sc
le
w
ea
k
n
es
s
(l
o
w
er
li
m
b
s)
A
b
ro
th
er
af
fe
ct
ed
Y
es
Y
es
H
y
p
o
th
y
r.
W
it
h
in
lo
w
er
n
o
rm
al
li
m
it
s
N
o
n
e
P
re
v
io
u
s
M
I.
A
t
ec
h
o
ca
rd
io
g
ra
p
h
y
E
F
6
0
%
.
F
ir
st
d
eg
re
e
A
V
b
lo
ck
(P
R
2
4
2
m
s)
R
B
B
B
M
il
d
im
p
ai
rm
en
t
o
f
th
e
fr
o
n
ta
l
ex
ec
u
ti
v
e
fu
n
ct
io
n
s
M
y
o
to
n
ia
,
m
y
o
p
at
h
ic
re
cr
u
it
m
en
t,
n
o
n
eu
ro
p
at
h
y
3
P
t
4
9
0
0 re
p
ea
ts
3
2
2
8
P
ro
g
re
ss
iv
e
w
ea
k
n
es
s
o
f
fa
ci
al
an
d
h
an
d
m
u
sc
le
s
A
si
st
er
an
d
h
is
m
at
er
n
al
au
n
t
af
fe
ct
ed
.
P
ro
b
ab
ly
h
is
g
ra
n
d
m
o
th
er
w
as
al
so
af
fe
ct
ed
N
o
N
o
N
o
d
u
le
s
N
o
rm
al
N
o
n
e
E
v
id
en
ce
o
f
1
st
d
eg
re
e
A
V
b
lo
ck
(P
–
R
in
te
rv
al
=
2
4
0
m
s)
an
d
H
–
V
in
te
rv
al
[
7
0
m
s
at
E
P
S
w
it
h
im
p
la
n
t
o
f
P
M
,
an
d
la
te
r
u
p
g
ra
d
e
to
IC
D
N
o
rm
al
M
y
o
to
n
ia
,
m
y
o
p
at
h
ic
re
cr
u
it
m
en
t,
n
o
n
eu
ro
p
at
h
y
3
P
t
5
9
7
0 re
p
ea
ts
7
8
2
0
H
an
d
g
ri
p
m
y
o
to
n
ia
T
w
o
o
f
h
is
si
st
er
s
p
ro
b
ab
ly
af
fe
ct
ed
Y
es
N
o
N
o
M
il
d
re
st
ri
ct
iv
e
lu
n
g
d
is
ea
se
th
at
re
q
u
ir
ed
la
te
r
n
o
n
-
in
v
as
iv
e
v
en
ti
la
ti
o
n
N
IV
d
u
ri
n
g
sl
ee
p
N
o
n
e
In
it
ia
ll
y
d
et
ec
ti
o
n
o
f
fi
rs
t
d
eg
re
e
A
–
V
b
lo
ck
,
la
te
r
im
p
la
n
t
o
f
lo
o
p
re
co
rd
er
b
ec
au
se
o
f
sy
n
co
p
al
ep
is
o
d
es
n
o
t
as
so
ci
at
ed
w
it
h
si
g
n
ifi
ca
n
t
ab
n
o
rm
al
it
ie
s
at
an
ex
te
n
si
v
e
d
ia
g
n
o
st
ic
ca
rd
io
lo
g
ic
as
se
ss
m
en
t
al
so
in
cl
u
d
in
g
an
E
P
S
(H
–
V
in
te
rv
al
=
7
0
m
s)
N
o
rm
al
M
y
o
to
n
ia
,
m
y
o
p
at
h
ic
re
cr
u
it
m
en
t,
n
o
n
eu
ro
p
at
h
y
4
E
C
G
H
o
lt
er
m
o
n
it
o
ri
n
g
,
ec
h
o
ca
rd
io
g
ra
p
h
y
,
E
P
C
ec
to
p
ic
p
re
m
at
u
re
co
m
p
le
x
,
H
V
h
is
-v
en
tr
ic
le
,
M
A
S
sy
n
d
ro
m
e
M
o
rg
ag
n
i–
A
d
am
s–
S
to
k
es
sy
n
d
ro
m
e,
M
E
P
m
ax
im
u
m
ex
p
ir
at
o
ry
p
re
ss
u
re
,
M
I
m
y
o
ca
rd
ia
l
in
fa
rc
ti
o
n
,
M
U
A
P
m
o
to
r
u
n
it
ac
ti
o
n
p
o
te
n
ti
al
,
N
A
D
n
o
ab
n
o
rm
al
it
y
d
et
ec
te
d
,
P
E
F
p
ea
l
ex
p
ir
at
o
ry
fl
o
w
,
R
B
B
B
ri
g
h
t
b
u
n
d
le
b
ra
n
ch
b
lo
ck
,
V
T
v
en
tr
ic
u
la
r
ta
ch
y
ca
rd
ia
,
N
C
S
n
er
v
e
co
n
d
u
ct
io
n
st
u
d
y
J Neurol
123
Patients 4 and 5 had already received a genetic diagnosis
of DM1 by LR PCR/Southern blotting at our department
(Fig. 1).
DNA extraction and LR-PCR
A written informed consent for DM1 molecular testing was
obtained from all patients. Genomic DNA was extracted
from peripheral blood lymphocytes and muscle biopsies by
the Wizard Genomic DNA Purification Kit (Promega,
Woods Hollow Road Madison, USA). LR-PCR/Southern
blot, routinely used for DM1 molecular diagnosis was
performed as described previously [20].
Bidirectional triplet primed PCR
Bidirectional TP-PCR was performed using ‘‘Expand Long
Template PCR System Kit’’ (Roche Diagnostics, Mann-
heim, Germany) which includes a combination of two
thermostable Taq polymerases. A negative and a positive
control (DM1 with positive long-range testing) were also
included in each set of reactions.
For the ‘‘forward’’ reaction 50–150 ng of DNA were
amplified in a reaction volume of 25 ll, using 2.5 units of
DNA polymerase mix, Buffer 1 1X, 0.8 lM of primers
6-FAM labeled-DM1 F 50-GCT CGAAGGGTCCTTGTAG
CCG-30, P3 (tail) 50-TACGCATCCCAGTTTGAGACG-30
and 0.08 lM of the primer DM1/CAG R 50-tacgcatcccag
tttgagacgCAGCAGCAGCAGCAGCAGCAGCAG-30,
Betaine 1.3 M, 0.4 lM of each dATP, dCTP, dTTP, and dGTP.
Cycling conditions were:10 min/98 C, 15 s/94 C, 30 s/
62 C, 5 min/68 C for 10 cycles; 15 s/94 C, 30 s/62 C,
5 min/68 C, 20 s/68 C for 25 cycles and 7 min/68 C.
Standard reverse TP-PCR was performed using the
following primers: 6-FAM labeled-DM1 R 50-CCTGCAG
TTTGCCCATCCACG-30, P3 (tail) and DM1/CTG F 50-
tacgcatcccagtttgagacgTGCTGCTGCTGCTGCTGCTG-30.
Patients showing an aberrant pattern at standard reverse
TP-PCR (Supplementary Fig. 1B) were further assessed by
a second round of reverse TP-PCR and subsequent
sequencing studies using in the reactions primers DM1/CC
F 50-tacgcatcccagtttgagacgTGCTGCTGCTGCTGCTGCT
GCC-30 and DM1/CCG F: 50-tacgcatcccagtttgagacgTGCC
GCTGCCGCTGCCGCTGCC-30, that allow to identify
variant expansions containing CCG interruptions at the 30
end of the CTG array at the DMPK locus [12].
For capillary electrophoresis, 2 ll of the TP-PCR
products were analyzed on an ABI 3130 automatic
sequencer using GS500 LIZ (Applied Biosystems, Foster
City, USA) as internal markers.
Sequencing
Both forward and reverse (using primer DM1 CC F) TP-
PCR products were purified using SureClean (Bioline,
London, UK) and directly sequenced using unlabeled DM1
F and DM1 R respectively on an ABI 3130 automatic
sequencer and BigDye XTerminatorTM Purification Kit
(Applied Biosystems, Foster City, USA).
Fluorescent-PCR
The sizing of the variant alleles was assessed on leukocytes
DNA from pts 1–3 and from one typical DM1 patient by
fluorescent PCR using the Expand Long Template PCR
System Kit (Roche Diagnostics, Mannheim, Germany) [21,
22]. Reaction conditions included buffer one with 10 %
DMSO, 0.4 lM of each dATP, dCTP, dTTP, and dGTP,
15 pmol of the forward primer 6-FAM labeled-MDY 1D
and 15 pmol of the reverse primer MDYZ2A [20].
2 kb
3.8 kb
5 kb
Normal
allele
Expansion
range
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Fig. 1 LR-PCR/Southern blot. For each sample, reactions were
performed in duplicate: lanes 1–6 = pts 1–3; lanes 7–10 = pts 4–5;
lanes 11–12 = control; lanes 13–14 = DM1 patient. Fragments
corresponding to wild-type alleles show a molecular weight (MW)
of about 2 kb. The DM1 patient shows fully expanded alleles with
MW between 2.8 and 3.8 kb. Pts 1–3 show an apparent homozygosity
for a wild-type allele; expanded alleles between 3.8 and 5 kb were
also detected in pts 4 and 5 by this procedure
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Cycling conditions were: 10 min/98 C, 15 s/94 C, 30 s/
62 C, 5 min/68 C for 10 cycles; 15 s/94 C, 30 s/62 C,
5 min/68 C, 20 s/68 C for 25 cycles and 7 min/68 C.
5 ll of the PCR products were analyzed on ABI 3130
automatic sequencer using GS1200 LIZ (Applied Biosys-
tems, Foster City, USA) as internal markers.
The size of expanded alleles was estimated by Southern
blot analysis of fluorescent PCR products: briefly, after
amplification 15 ll of reaction products were separated by
electrophoresis overnight at 40 V in 1 % agarose gel. Gels
were then blotted and hybridized with (CTG)5 32P-labeled
oligonucleotide. After two washes in 3xSSC and 0.1 % SDS at
44 C, filters were exposed to Biomax MR autoradiography
films (Kodak film, Rochester, USA) for 2 h at -80 C.
Muscle RNA-FISH-immunofluorescence (FISH-IF)
for MBNL1
6 lm-thick, serial transverse muscle cryostat sections from
pts 1–3 and one typical DM1 patient were processed as
previously described [23].
In order to get the same treatment, muscle sections from
control and three patients were placed on the same slide.
Muscle sections were examined using a fluorescence
microscope (Olympus BH2-RFCA).
Muscle RT-PCR studies
Total RNA was extracted from muscle tissues using Trizol
reagent (Invitrogen, Carlsbad, California), according to the
manufacturer’s instructions. The first strand cDNA was syn-
thesized using 1 lg of total RNA DNaseI treated, 100 ng
oligo(dt)12–18 primer (Invitrogen, Carlsbad, California),
0.5 mM dNTPs and 200 units SuperScript II reverse trans-
criptase (Invitrogen, Carlsbad, California) at 42 C for 1 h.
For RT-PCR studies of INSR, TNNT2, RYR1 and CLCN1
mRNAs, PCR amplification of the individual cDNA frag-
ments was carried out using oligonucleotides previously
described [24–27].
RT-PCR products were resolved on 8 % non-denaturing
polyacrylamide gels and stained with ethidium bromide.
Densitometric analysis was carried out using the TotalLab
12.01 software (Nonlinear Dynamics Ltd., Newcastle upon
Tyne, UK); the relative amount of each aberrant pre-
mRNA specie was estimated as percentage value of the
aberrant isoform versus its corresponding total pre-mRNA.
Results
TP-PCR analysis
In pts1–3, routine DM1 testing by long-range PCR showed
a unique band in the range of normal alleles (Fig. 1).
In order to rule out false negative results, we therefore
decided to perform bidirectional TP-PCR. This analysis
showed two close peaks both in the normal range in the
healthy heterozygous subject (data not shown). In the
canonical DM1 patient, the electropherogram showed a
ladder peak in the pathological range whose height
diminished gradually with increasing product size both for
the forward and the reverse TP-PCR reactions (Fig. 2b).
In pts 1–3 the ‘‘forward’’ TP-PCR clearly documented
pathologically expanded alleles similar to those ones
detected in the non-variant DM1 patient (Fig. 2c, left
panel). Moreover, the electropherograms of the ‘‘reverse’’
TP-PCR using DM1/CTG F showed an aberrant pattern
with a drop in the intensity signal, suggestive for the
presence of variant DM1 expansions (Supplementary
Fig. 1B, left panel).
Accordingly, ‘‘reverse’’ TP-PCR performed using
either DM1/CC-F (Fig. 2c, right panel) and DM1/CCG-F
(Supplementary Fig. 1B, right panel) revealed repeated,
regular interruptions within the ladder peak only in these
patients; in this regard, and in agreement with previous
data [16], our results indicate that the proofreading
activity of the polymerase would overcome in some cases
the presence of few mismatches in the oligonucleotide
sequences.
Sequence analysis of the forward TP-PCR products of
pts 1–3 using an unlabeled DM1F primer documented a
long run of pure CTG repeats without interruptions, similar
to canonical DM1 patients (Supplementary Fig. 2A–C, left
panels).
Conversely, sequence analysis of reverse TP-PCR
products using an unlabeled DM1 R primer documented in
these patients novel arrays of interruptions of the typical
CTG stretch by CCG trinucleotides located in the distal 30
end of the repeat (CCGCTGCTGCCG) (Supplementary
Fig. 2): in particular, pt 1 had genotype (CTG)5(CCGCTG
CTG)46, Pt2 had genotype (CTG)9(CCGCTGCTG)61
(Supplementary Fig. 2A and B, right panels). Upstream of
these regions, the sequences became uncertain (CT/CG)n in
both patients, probably because of sequencing and PCR
artifacts and/or possible somatic mosaicism [12].
Also in pt 3, sequence analysis confirmed an interrupted
array, characterized by (CTG)3 followed by uncertain
(CTG/CCG)5 (Supplementary Fig. 2C, right panel).
Fluorescent-PCR for repeat size assessment
Fluorescent-PCR is currently used for the molecular diag-
nosis of genetic diseases associated with pathologically
expanded alleles repeats [21, 22]. This technique allows to
assess the size of expanded alleles containing up to 320
triplet repeats, while the size of larger expanded alleles
cannot be estimated [21, 22].
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By fluorescent PCR we were able to assess the size of
the variant expanded allele in leukocytes DNA from pt 3,
estimating an allele containing about 65 repeats (Fig. 3d)
while, according to the sensitivity of this technique [21,
22], both pt 1 and pt 2 showed an expanded allele greater
than 320 triplets (Fig. 3b, c). The size of variant expanded
alleles in these two patients was then estimated by South-
ern blot analysis of fluorescent PCR products.
This analysis documented a smearing signal between 1.6
and 2.1 kb corresponding to alleles carrying 550–700
repeats in pt 1, while pt 2 showed a smearing signal
between 1.8 and 2.5 kb (600–830 repeats) (Fig. 3e). In pt
3, sizing by Southern blot was comparable to that ascer-
tained by capillary electrophoresis (one allele of 0.5 kb
corresponding to about 65 repeats, Fig. 3d, e).
Muscle RNA-FISH-immunofluorescence studies
In DM1 pathology, the RNAs containing CUG expansions
fold into hairpin structures and accumulate in nuclear foci,
interfering with the activities of specific RNA-binding
protein families, the muscleblind-like, which regulate the
alternative splicing of several genes [28, 29].
To investigate if the presence of the CCG interruptions
within the CTG array might lead to modifications in the
higher structure of RNA transcripts and/or their interactions
with RNA binding proteins, we performed RNA-FISH-
immunofluorescence analysis with CAG probe and MBNL1
antibody on 6-lm muscle sections available from pts 1–3.
In all three patients studied, FISH using a CAG probe
documented the presence of several ribonuclear inclusions
per nucleus (Fig. 4a, d, g and k); MBNL1 immunofluo-
rescence studies showed its co-localization with the ribo-
nuclear foci, similar to what observed in a canonical DM1
patient (Fig. 4c, f, i and l).
Alternative splicing analysis of developmentally
regulated exons
To determine whether the presence of CCG interruptions
would influence the aberrant alternative splicing pattern
observed in DM1 tissues [24–27], we analyzed the splicing
pattern of INSR, TNNT2, RYR1and CLCN1 in muscle RNA
from two controls, two canonical DM1 patients and pts 1–3
(Fig. 5). Indeed, all alternative splicing analyzed by den-
sitometric analysis resulted similarly mis-regulated in pts 1–3
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Fig. 2 Analysis of CTG repeats at the DMPK locus by bidirectional
TP-PCR. a Genomic organization around the DM1 expansion. Coding
regions of DMPK and SIX5 are pictured as black boxes, CTG repeat
region as white box and intronic sequences as thick black line. The
PCR primers used in this study are indicated as arrows. DNA from
patients was amplified using DM1/CAG R in the forward TP-PCR
(green) and DM1/CC F in the reverse TP-PCR (blue). The yellow
peaks correspond to the GS500 LIZ (Applied Biosystems, Foster City,
USA) marker. b TP-PCR of a canonical DM1 patient. c TP-PCR of
Pt1: the forward reaction documented pathologically expanded alleles
with a pattern similar to the canonical DM1 patient; the electropher-
ograms of the reverse TP-PCR displayed closely repeated gaps within
the ladder peak. Similar data was obtained in pts 2 and 3 (data not
shown)
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as well as in two non-variant DM1 patients, showing a relative
increase in the embryonic splice variants (Fig. 5).
Prevalence of variant repeats in DM1 families
By reverse TP-PCR, we screened 100 index cases of dis-
tinct genetically confirmed DM1 families diagnosed by LR
PCR/Southern blot, to assess the prevalence of variant
repeats in our cohort of study; this screening documented a
pattern suggestive of variant repeats in 2 out of 100 patients
tested (Pts4–5 of this study) (Fig. 6a, b).
Sequence analysis confirmed the presence of CCG
interruptions also in these patients. However, in these cases
the CCG repeats were more scattered along the CTG array
compared to pts 1–3: in particular, pt 4 had genotype
(CTG)16 CCG(CTG)4 CCG(CTG)8 CCG(CTG)5CCG(CTG)2
CCG(CTG)2 CCG(CTG)8, while Pt5 had genotype (CTG)12
CCG(CTG)6 CCG(CTG)5 CCG(CTG)5. Again, upstream of
these regions, sequences became unreadable; moreover,
sequence analysis of the forward TP-PCR products using an
unlabeled DM1F primer documented also in these cases a pure
CTG stretch (Supplementary Fig. 3). The size of the expanded
alleles, estimated by LR PCR/Southern blot was about 900
repeats in pt 4 and 970 repeats in pt 5 (Fig. 1).
Overall we estimated a prevalence of 4.8 % (5/103)
variant expansions in our cohort of DM1 families.
Discussion
Expansion disorders are caused by a dynamic mutation
(polymorphic short tandem repeats, interspersed within the
gene sequences), arising through DNA replication and
repair. Most frequently, pathological expansions involve
trinucleotide repeats, including CAG, CTG, CGG and
GAA within exons or in the untranslated gene regions [30].
Such polymorphic tracts are short and stable in healthy
individuals, while in affected families the tracts are longer
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Fig. 3 Chromatograms of fluorescent PCR performed on leukocytes
DNA from pts 1–3 and one DM1 patient. The yellow peaks
correspond to the GS1200 LIZ (Applied Biosystems, Foster City,
USA) marker. Asterisks indicate the wild-type allele (around 256 bp).
The light blue square indicates the interval in which it is not possible
to assess the size of expanded alleles. Canonical DM1 patient (a), Pt 1
(b) and Pt 2 (c) carry an allele containing [320 repeats; Pt 3 (d) has
about 65 repeats. e Southern blot analysis of fluorescent PCR
products. Wild-type alleles show a molecular weight (MW) of about
0.25 kb. As an internal standard, a canonical DM1 patient shows a
fully expanded allele with a range of 1,200–1,700 repeats (smear
between 3.6 and 5.1 kb). Pt 1 carries about 550–700 repeats (smear
between 1.6 and 2.1 kb), while in pt 2 the expansion contains about
600–830 repeats (smear between 1.8 and 2.5 kb). In pt 3, such a test
confirms the result obtained with fluorescent PCR (band around
0.5 kb, about 65 repeats)
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and unstable. They have a strong tendency to expand rather
than contract themselves during intergenerational and
somatic divisions.
In contrast to other triplet repeat disorders, in which the
presence of interruptions within the expanded array are
widely documented, the pathological expansion associated
Fig. 4 RNA-Fluorescence in situ hybridization (RNA-FISH) and
immunofluorescence (IF) studies for MBNL1 on muscle sections of
Pt1–3 and a canonical DM1 patient. RNA-FISH using (CAG)6CA
probe conjugated with 50 fluorescein (FAM) (a, d, g and k panels,
green) combined with IF using MBNL1 monoclonal antibody HL
1822 [3A4-1E] (b, e, h and j panels, red) shows ribonuclear foci that
co-localize with the signal for MBNL1 in muscle nuclei (c, f, i and
l panels, nuclei counterstained in blue by DAPI). Scale bar 20 lm
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with DM1 has been assumed to be a pure CTG repeat [3, 5,
6]. The one exception to this was represented by a ‘37’
repeat allele containing CCG interruptions identified in an
anonymous sperm donor [31].
However, two research studies recently documented vari-
ant DM1 expanded alleles, characterized by the presence of
CCG, CTC and/or GGC interruptions in the regular primary
structure of the 30-end of the CTG array, with a prevalence of
5 % and 3–4 % in their respective cohorts [11, 12].
The detection of variant DM1 alleles containing inter-
ruptions within the CTG array raised several important
issues. First, the presence of GC interruptions at the 30-end
of the CTG array may lead to atypical (presence of gaps in
the repeat primed-PCR ladder) or ambiguous (positive by
Southern blot analysis of genomic DNA, but negative by
repeat primed PCR and/or amplification across the array)
results at routine molecular testing, possibly leading to
false negative results [11, 16].
Moreover, variant DM1 alleles frequently showed a
relatively shorter size and they were also characterized by a
greater inter-generational stability [11, 12]. Such evidence
suggested that interruptions within the CTG array could
have a stabilizing effect not only on the interrupted tract
itself but also on the proximal, uninterrupted expanded
CTG stretch, likely altering the binding of cis-elements that
regulate the stability of the repeat [11].
Finally, the association of specific clinical features not
typical of DM1 in some families carrying variant
Ex 4                Ex 5                 Ex 6
Exon 5 (+)
Exon 5 (-)
INSR
Ex 10              Ex 11               Ex 12
Exon 11 (+)
Exon 11 (-)
Ex 69               Ex 70               Ex 71
Exon 70 (-)
Exon 70 (+)
Ex 4                 Ex 5                 Ex 6                Ex 7a               Ex 7                 Ex 8
Exon 7a (+)
Exon 7a  (-)
Ex 4      Ex 5      Ex 8
CLCN1
β-actin
RYR1 ASI
TNNT2
Ct        Ct         DM1     DM1    Pt1       Pt2        Pt3
E1
1 
(-)
 %
E5
 (+
) %
0
20
40
60
0
E7
0 
(-)
 %
0
10
20
30
40
50
60
E7
a 
(+
) %
40
60
80
100
0
20
40
60
Fig. 5 Semi-quantitative RT-
PCR analysis on total RNA
extracted from muscle biopsies
of pts 1–3, two controls (CT)
and two canonical DM1 patients
(DM1); the b-actin signal was
used as reference standard.
Right panel scheme of the exon/
intron layout of human INSR,
TNNT2, RYR1 and CLCN1.
Exons and introns are
represented as thick and thin
boxes respectively. Left panel;
in pts 1–3 show an aberrant
splicing of all these genes,
similar to that found in the DM1
patients; histograms on top of
each gel represent the relative
amount of each aberrant pre-
mRNA specie, estimated as
percentage values of the
aberrant isoform versus its
corresponding total pre-mRNA
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expansions suggested that these interruptions might mod-
ulate the clinical phenotype, possibly affecting the mutational
dynamics of the variant expansions within individual tissues,
the formation of RNA foci and/or their interaction with
splicing factors involved in DM1 pathogenesis [11, 12].
To clarify these issues, we searched for the presence of
variant expansions in our cohort of patients clinically
affected by Steinert’s disease; the group of study included
three patients repeatedly testing negative for DM1 and 100
index cases belonging to unrelated DM1 families previ-
ously diagnosed at our center by routine LR-PCR/Southern
blotting [20].
In agreement with previous studies, our results confirm
that the presence of CCG interruptions at the 30-end of the
expanded CTG array at the DMPK locus can affect PCR
amplification of the variant expansions, in some cases with
a misleading negative result (Fig. 1).
Indeed, three of our five variant DM1 patients were
apparently homozygous for a wild-type allele at routine
DM1 molecular testing.
However, all of them showed both clinical (Table 1) and
muscle morphological features (centralized nuclei, ring
fibers and preferential type I fiber atrophy, data not shown),
highly suggestive of DM1 [32].
10000
20000
30000
40000
190 290 390 490 590 690 790
0
Pt 4
8000
16000
24000
32000
100 200 300 400 700600500
Pt 5
0
A
B
CGG
Fig. 6 Analysis of the DMPK locus by reverse TP-PCR using oligo
DM1/CC F. a The electropherogram of pt 4 shows several gaps in the
fluorescent peak suggestive for variant expansions. Direct sequencing
of the reverse TP-PCR products using the antisense oligonucleotide
(DM1 R) confirmed the presence of CCG interruptions (black boxes)
in the typical CTG repeats. b Similar findings were obtained in Pt5
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Thus, we strongly reconsidered such a diagnosis. With
regards to recent literature [11, 12] we searched for variant
expansions using bidirectional TP-PCR; the forward reac-
tion amplified a pathologically expanded allele in all of
them, and the reverse reaction using modified oligonucle-
otides containing either CC (DM1/CC F) or CCG (DM1/
CCG F), showed discontinuous signals in the fluorescence
peaks, likely caused by the presence of interruptions in the
CTG array [12, 16].
Sequencing of TP-PCR products confirmed the presence
of CCG interruptions at the 30-end of the CTG array, while
the CTG stretch resulted uninterrupted at its 50-end (Fig. 2,
Supplementary Fig. 2).
The application of the screening by reverse TP-PCR to
our DM1 cohort, including 100 unrelated families, enabled
us to identify two other patients carrying variant expan-
sions. Also in these cases, sequence analysis confirmed the
presence of CCG interruptions at the 30-end of the array.
In all variant cases, we identified novel patterns of
expanded arrays (Supplementary Fig. 2 and Fig. 6);
intriguingly, our data would suggest that different gaps of
CCG interruptions within the CTG array might influence
the LR-PCR amplification of variant expanded DM1
alleles, possibly affecting their higher DNA structure.
Indeed, LR-PCR failed to amplify expanded alleles of pts
1–3 (Fig. 1), characterized by regular, tightly spaced CCG
interruptions (Supplementary Fig. 2), while it successfully
amplified the expanded repeats in pts 4–5 (Fig. 1), showing
more irregular and scattered CCG interruptions (Fig. 6).
Thus, regarding DM1 molecular diagnosis, a proposed
diagnostic algorithm should consist of a short PCR to
bridge the repeat, followed by TP-PCR in cases showing
just one allele. If both tests are negative but the clinical
suspicion of DM1 remains high, classic Southern blot on
genomic DNA should be performed to definitively exclude
the presence of a pathological expansion at the DMPK
locus [33].
We estimated a prevalence of 4.8 % of variant expan-
sions in our DM1 population, similar to two previous
studies [11, 12]. Indeed, such estimation defines the lower
limit in our population, since this screen would only be
able to detect variant repeats that are reasonably close to
either the 30- or 50-end of the array, while small numbers of
variant and/or variants further from either end of the array
may be undetected [16].
Interestingly, two studies concerning large cohorts of
DM1 parent-offspring pairs documented repeat contrac-
tions in 4–6 % of cases, a percentage very close to that
estimated for variant expansions [34, 35]. Unfortunately,
we did not have the chance of studying any first-degree,
affected relatives of our variant DM1 patients, but the lit-
erature has shown that variant DM1 alleles have a greater
intergenerational stability than uninterrupted ones, being
even biased toward contraction [11, 12]. Therefore, in
relation to genetic counseling, further studies are needed to
clarify if repeat contractions occur only for variant DM1
alleles during intergenerational transmission.
Regarding the clinical phenotype associated with variant
DM1 expansions, one of the families diagnosed by Braida
et al. [11] co-segregated a complex neurological phenotype
variably including an intermediate CMT neuropathy, early
hearing loss and encephalopathic attacks. Such a complex
phenotype is clearly distinct from that observed in other
variant DM1 patients described until now [11, 12], as well
as in our cases (Table 1). The peculiar phenotype observed
in such a family [11] could be either related to the specific
sequence and combination of repeat variants present on
that particular DM1 mutated allele (the only being char-
acterized by GGC variant repeats and a perfect 9 bp CGG/
CCG hairpin structure), or to the occurrence of a co-seg-
regating mutation in the MYH14 gene, which is closed to
DMPK and mutations of which have been recently
described in a family manifesting a complex neuropathy
phenotype [36].
Overall, our variant DM1 patients displayed a typical
DM1 phenotype (Table 1). Muscle MRI findings were also
comparable to those reported in DM1, showing in the three
cases examined a predominant involvement of the leg and
posterior thigh muscles [37, 38].
The only difference with canonical DM1 patients might
be represented by the lack of cognitive involvement.
Although it is known that an age-dependent cognitive
decline mainly involving frontal and temporal functions
can occur in DM1 patients [18, 39, 40], none of our variant
DM1 patients, whose average age was 60.4 years, showed
a significant cognitive impairment at neuropsychological
examination (Table S1).
In this regard, it has been documented that DM1 tissues
show a different degree of somatic mosaicism [41–43] and
that either changes in the methylation status of the
expanded allele [44] and/or binding of specific regulatory
factors to cis-elements flanking the repeat may influence
the somatic instability at the DMPK locus [45]. Therefore,
we may speculate that the presence of CCG interruptions
within the expanded CTG array could affect one of these
mechanisms, eventually leading to an increased stability of
the variant DM1 allele particularly in the brain tissue.
Studies on larger cohorts of variant DM1 patients will be
helpful to clarify this issue.
Concerning genotype-phenotype correlations (similar to
the canonical DM1 patients), also in our ‘‘variant’’ DM1
patients the size of variant expansions in leukocytes cor-
related with the age at onset of symptoms. Pts 1 and 2
(harboring shorter expansions had the onset of symptoms in
their 50s, while in pts 4 and 5 (carrying larger expanded
alleles), the onset occurred during the third decade of life
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(Table 1). Pt 3 carried approximately 65 repeats in leuko-
cytes and from the age of 30 years developed a progressive
eyelids ptosis, but she manifested skeletal muscle weakness
only in her late 60s.
Previous studies [11, 12] hypothesized that the presence
of interruptions in the regular primary structure of the
expanded CTG tract could lead to conformational changes
in the higher structure of the RNA transcripts, eventually
affecting their toxic gain of function.
To address this topic, we analyzed muscle biopsies
available from three out of our five variant DM1 patients.
RNA-FISH using a CAG probe, combined with immuno-
fluorescence for MBNL1 protein revealed the presence of
nuclear foci and their co-localization with MBNL1
(Fig. 4c, f, i and l), similar to what documented in
canonical DM1 patients [23]. Moreover, we documented an
aberrant alternative splicing of developmentally regulated
exons involved in DM1 pathogenesis [24–27], with no
obvious differences between patients with and without
variant expansions (Fig. 5).
Thus, our results indicate that the presence of CCG
interruptions do not considerably affect the toxic gain
of function of expanded RNAs [45, 46], at least in those
patients carrying a pattern of DNA rearrangement
similar to pts 1–3 (CCGCTGCTG). On the other hand,
future muscle studies in DM1 patients carrying various
patterns of interruptions will address if changes in the
array of the variant repeat would differently affect the
accumulation of RNA foci and/or their co-localization
with MBNL1.
In summary, our study documents for the first time that
variant DM1 patients do not appear to present with par-
ticularly unusual symptoms and that characteristic MBNL1
positive ribonuclear foci and splicing defects are also
observed in their muscle tissues. Our data also suggests that
the presence of CCG interruptions at the 30-end of expan-
ded DMPK alleles might modulate the clinical phenotype
by affecting the mutational dynamics of the variant repeats:
in this regard, we now plan to analyze the somatic stability
of variant DM1 expansions in fibroblasts cell cultures
available from some of our patients.
Finally, this study confirms that bidirectional TP-PCR is
very sensitive to detect ‘‘variant’’ DM1 expansions, and
that this technique should be included in the routine diag-
nostic protocol used for DM1 testing [47].
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